摘要
目的:观察重组人干扰素栓治疗宫颈人乳头瘤病毒(HPV)感染的疗效。方法:宫颈HPV感染患者128例随机分为观察组和对照组各64例。观察组患者采用重组人干扰素α-2b栓治疗,对照组采用保妇康栓治疗,疗程均为30 d。比较两组疗效及两组治疗前后HPV的E6/E7 m RNA、p16和p53表达情况。结果:观察组有效率为93.75%,明显优于对照组的84.38%(P<0.05)。治疗后,两组CINⅠ级、CINⅡ级、CINⅢ级、尖锐湿疣和宫颈癌的E6/E7m RNA、p16和p53表达量中位数(M)、阳性表达率等指标与本组治疗前比较,差异有统计学意义(P<0.05)且两组间比较,差异有统计学意义(P<0.05)。治疗后,两组不同疾病类型患者E6/E7m RNA、p16和p53表达量和阳性表达率与本组治疗前比较,差异有统计学意义(P<0.05),且两组间比较,差异有统计学意义(P<0.05)。结论:采用重组人干扰素α-2b治疗宫颈HPV感染疾病疗效较好,不良反应轻,且可降低HPV E6/E7m RNA、p16和p53的表达量与阳性表达率。
Objective：To observe the efficacy of human interferon alpha-2b in the patients with HPV infection.Methods：Totally 128 patients with HPV infection were divided into two groups by the random number table with 64 cases in each.The patients in the observation group were treated with human interferon alpha-2b and those in the control group were treated with Baofukang suppositories.The course of treatment was 30 days for two groups.The expression level of HPV E6/E7 m RNA,p16 and p53 before and after the treatment and the severe adverse reactions in each group were studied.Results：The effective rate of the observation group was 93.75%,and that of the control group was 84.38%（P〈0.05）,the effictive rate of the observation group was better than the control group.After the treatment,the median（M） and the positive expression rate of E6/E7 m RNA,p16 and p53 in the two groups were significantly changed when compared with those before the treatment（P〈0.05）,and the difference between the two groups was also significant（P〈0.05）.After treatment the expression and the positive rate of E6/E7 m RNA P16 and P53 for different types of diseases in two groups were significanst difference（P〈0.05）,comparisons the parameters between groups were significant difference（P〈0.05）.Conclusion：The clinical efficacy of recombinant human interferon alpha-2b for HPV infection is better and the adverse drug reactions are mild,which can reduce the expression and positive rate of E6/E7 m RNA,p16 and p53 in the patients with HPV infection.
出处
《中国药师》
CAS
2016年第5期914-916,共3页
China Pharmacist
